25th week of 2022 patent applcation highlights part 34 |
Patent application number | Title | Published |
20220195377 | METHODS AND SYSTEMS FOR STABILIZATION AND PRESERVATION OF MICROBES - The present disclosure relates to methods of stabilization of microbial compositions comprising combining a population of pre-served microbial cells with at least one water activity scavenger (WAS) to a desired homogeneity level; and packaging and sealing the mixture of preserved microbial cells and the WAS. The present disclosure further relates to the stabilized microbial compositions and uses thereof. | 2022-06-23 |
20220195378 | METHOD FOR PREPARING A BIOMASS OF STABLE FREEZE-DRIED BACTERIAL CELLS AND DETERMINING THE STABILITY THEREOF BY MEANS OF A CYTOFLUOROMETRY METHOD - A biomass of freeze-dried bacterial cells and related devices, compositions and method of preparation are described. The method comprises (i) fermenting a previously prepared biomass of bacterial cells (bacterial biomass) to obtain a biomass of fermented bacterial cells (fermented biomass); (ii) concentrating the fermented biomass obtained from step (i) up to obtaining a biomass of concentrated bacterial cells (concentrated biomass) having a bacterial cell concentration comprised from 1×10 | 2022-06-23 |
20220195379 | METHOD OF TESTTING INHIBITORY EFFECT OF CARBON DIOXIDE ON SPOILAGE CAUSING ABILITY OF SHEWANELLA PUTREFACIENS - Disclosed is a method of testing an inhibitory effect of carbon dioxide on a spoilage causing ability of | 2022-06-23 |
20220195380 | METHODS FOR TISSUE FABRICATION - Disclosed herein are improved methods for fabricating bioprinted, three-dimensional, biological tissues. The methods relate to exposures to low temperatures, incubations at low temperatures of various durations, and fabrication in environments without structural cross-linking treatments. | 2022-06-23 |
20220195381 | CELL CULTURE SUBSTRATE FOR CULTIVATING ADHERENT CELLS - A cell culture substrate for cultivating adherent cells, including:
| 2022-06-23 |
20220195382 | A NOVEL HUMAN-MATERIAL-BASED PLATFOM TECHNOLOGY FOR TISSUE ENGINEERING - The present invention relates to a biologically active placenta-derived liquid human substrate (hpS) comprising extracellular matrix (ECM) proteins, cytokines and growth factors and use thereof. The present invention also provides methods of producing a composition comprising biologically active placenta-derived liquid human substrate (hpS). | 2022-06-23 |
20220195383 | METHOD FOR PRODUCING PLURIPOTENT STEM CELLS - A method for producing pluripotent stem cells includes a step of performing suspension culture of pluripotent stem cells under a condition in which an amount, which is calculated by the following Equation (1), of WNT protein contained in a unit of a medium in contact with a unit area of a cell surface of a pluripotent stem cell is maintained at 2.9×10 | 2022-06-23 |
20220195384 | COMPOSITION FOR PROMOTING PRODUCTION OF STEM CELL-DERIVED EXOSOMES AND INCREASING STEMNESS - The present disclosure relates to a composition for promoting the production of stem cell-derived exosomes or increasing the stemness of stem cells. When the composition of the present disclosure is used in culturing stem cells, the stemness of stem cells and the yield of stem cell-derived exosomes are increased, and thus good-quality stem cells and stem cell-derived exosomes can be produced more efficiently, and accordingly, can be advantageously used in related research and development and commercialization. | 2022-06-23 |
20220195385 | MOTILE CELL SORTING DEVICE - [Problem to be Solved] Provided is a motile cell sorting device that can effectively sort motile cells, such as sperms, having excellent motility and morphology by performing image analysis when animal cells are sorted. [Means for Solution] The motile cell sorting device | 2022-06-23 |
20220195386 | COMPOSITIONS AND METHODS FOR MAKING SENSORY NEURONS - The three main peripheral sensory neuron (SN) subtypes, nociceptors, mechanoreceptors, and proprioceptors localize to dorsal root ganglia (DRG) and convey sensations such as pain, temperature, pressure and limb movement/position. Disclosed herein is a chemically defined differentiation protocol that generates all three SN subtypes from the same starting population, as well as methods to enrich for each individual subtypes. The protocol yields high efficiency and purity cultures that are electrically active and respond to specific stimuli. Their molecular character and maturity stage are described and evidence for their use as an axotomy model is exemplified. Cell populations and compositions formed from the resulting cells, as well as methods of their use for disease treatment, drug screening, and modeling of human disorders affecting SNs are also provided. | 2022-06-23 |
20220195387 | COMPOSITIONS, APPARATUSES AND METHODS FOR MAKING AND USING BIOSCAFFOLDS - The present disclosure relates to compositions, apparatus and methods for generating one or more scaffolds, including: mixing a hydrogel material and/or an extracellular matrix (ECM) protein in an aqueous solvent to generate an aqueous process solution; and cryoelectrospinning the aqueous process solution onto a plurality of conductive probes extending from a conductive surface of a collector plate disposed within a process chamber under conditions sufficient to generate one or more scaffolds configured to mimic a preselected soft tissue decellularized extracellular matrix. Scaffold compositions are also provided having preselected or tuned characteristics. | 2022-06-23 |
20220195388 | METHODS, KITS AND APPARATUS FOR EXPANDING A POPULATION OF CELLS - The present invention relates to in vitro-methods of expanding a population of cells such as lymphocytes, comprising contacting a sample comprising a population of cells with a multimerization reagent. The multimerization reagent has reversibly immobilized thereon (bound thereto) a first agent that provides a primary activation signal to the cells and optionally, a second agent that provides a co-stimulatory signal. The invention also provides multimerization reagents, kits, arrangements and an apparatus for expanding cells. | 2022-06-23 |
20220195389 | METHODS OF IMPROVING THE LONGEVITY OF IMMUNE CELLS - Embodiments of the present disclosure pertain to methods of modifying immune cells by increasing the AMP-activated protein kinase (AMPK) activity of the immune cells in order to produce modified immune cells with enhanced longevity. In some embodiments, the methods of the present disclosure include one or more of the following steps: (1) obtaining immune cells from a subject; (2) increasing the AMPK activity of the immune cells; (3) expanding the modified immune cells; (4) introducing the modified immune cells to a subject; and (5) treating a disease in the subject. In further embodiments, the methods of the present disclosure include an in vivo method of increasing the AMPK activity of immune cells in a subject in order to treat a disease in the subject. Additional embodiments of the present disclosure pertain to the modified immune cells. | 2022-06-23 |
20220195390 | METHODS FOR PREPARING EXTRACELLULAR VESICLES (EV) DEPLETEMEDIA - Cell therapy is getting a growing interest in a wide range of indications in human. In many cases, a substantial part of the therapeutic effects relies on cell-secreted factors and the extracellular vesicles (EV) are proposed as a cell-free surrogate for cell therapy. Currently, during the EV production phase, human cells are placed in serum-free media to produce EV, with limited cell survival. Here, the inventors describe a new procedure for GMP-compatible human cells-derived EV wherein Human Platelet Lysate (HPL) is produced from which the EV are removed by tangential-flow-filtration resulting in an EV-depleted HPL. Said EV-depleted HPL may be then uses as a culture medium for the production of EV by cells of interest. | 2022-06-23 |
20220195391 | PLATELET-RICH PLASMA COMPOSITIONS AND METHODS OF PREPARATION - Methods are described for using compositions containing platelet-rich plasma for the treatment of a variety of tissue lesions, and the use of compositions containing platelet-rich plasma to accelerate or complete the differentiation of a cell line. Particularly, use of platelet-rich plasma in conjunction with cell differentiation. | 2022-06-23 |
20220195392 | METHODS AND COMPOSITIONS FOR CELL CULTURE ON HETEROGENEOUS SCAFFOLDS - Embodiments of the invention describe a cultured meat or food product with more desirable flavor and texture, as well as methods and compositions for producing the same. Certain embodiments are directed to methods of producing a stiffer, structured surfaces or scaffolds that mimic the extracellular matrix (ECM) and support the growth of myotubes that are interspersed with a scaffold component supporting fat cells (adipocytes) in vitro. | 2022-06-23 |
20220195393 | METHODS FOR STORAGE OF STEM CELLS - Described herein are methods and systems for preparing samples of stem cells for direct infusion. Some of the methods and systems described herein comprise hypothermic storage of the stem cells. The methods and systems described herein can supplement shipment of stem cells across long distances such that the stem cells are prepared for direct infusion upon receipt of the cells. | 2022-06-23 |
20220195394 | THREE-DIMENSIONAL PRINTED ORGANS, DEVICES, AND MATRICES - Provided herein are methods and systems for bio-printing of three-dimensional organs and organoids. Also provided herein are bio-printed three-dimensional organs and organoids for use in the generation and/or the assessment of immunological products and/or immune responses. Also provided herein are methods and system for bio-printing three-dimensional matrices. | 2022-06-23 |
20220195395 | PHYSIOLOGIC GROWTH OF CULTURED INTESTINAL TISSUE - The invention disclosed herein generally relates to methods and systems for improving physiological growth of cultured tissues. In particular, the invention disclosed herein relates to methods and systems for promoting maintenance of cultured intestinal organoids (e.g., derived from pluripotent stem cells or from primary sources such as biopsy tissue). | 2022-06-23 |
20220195396 | Genetically Engineered Cells and Uses Thereof - Provided are genetically engineered induced pluripotent stem cells (iPSCs) and derivative cells thereof expressing a chimeric antigen receptor (CAR) and methods of using the same. Also provided are compositions, polypeptides, vectors, and methods of manufacturing. | 2022-06-23 |
20220195397 | IMMUNE CELL CONTAINING TUMOR ANTIGEN RECOGNITION RECEPTOR AND APPLICATION THEREOF - A modified immune effector cell and a use thereof, a cell population containing the immune effector cell, and a pharmaceutical composition. The expression and/or activity of an S1PR1 protein of the modified immune effector cell is up-regulated. | 2022-06-23 |
20220195398 | ABHD5 AND PARTIAL HDAC4 FRAGMENTS AND VARIANTS AS A THERAPEUTIC APPROACH FOR THE TREATMENT OF CARDIOVASCULAR DISEASES - The present invention relates to Abhydrolase containing domain 5 (ABHD5) and N-terminal fragments of HDAC4 (HDAC4-NT) and variants of the aforementioned peptides for the treatment and prevention of heart failure. The present invention further provides vectors for the cardiomyocyte-specific expression of said peptides and a test system comprising ABHD5 for the identification of novel compounds which are useful for the treatment of heart failure. | 2022-06-23 |
20220195399 | SYNTHESIS OF GLUCAN COMPRISING BETA-1,3 GLYCOSIDIC LINKAGES WITH PHOSPHORYLASE ENZYMES - Reaction compositions are disclosed herein comprising at least water, alpha-glucose-1-phosphate (alpha-G1P), an acceptor molecule, and a beta-1,3-glucan phosphorylase enzyme. These reactions can synthesize oligosaccharides and polysaccharides with beta-1,3 glycosidic linkages. Further disclosed are methods of isolating beta-1,3-glucan. | 2022-06-23 |
20220195400 | ENGINEERED URIDINE PHOSPHORYLASE VARIANT ENZYMES - The present invention provides engineered uridine phosphorylase (UP) enzymes, polypeptides having UP activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing UP enzymes are also provided. The present invention further provides compositions comprising the UP enzymes and methods of using the engineered UP enzymes. The present invention finds particular use in the production of pharmaceutical compounds. | 2022-06-23 |
20220195401 | MODIFIED PIGGYBAC TRANSPOSASE POLYPEPTIDE, POLYNUCLEOTIDE ENCODING THEM, INTRODUCING CARRIER, KIT, METHOD OF INCORPORATING TARGET SEQUENCE INTO CELL GENOME, AND METHOD OF PRODUCING CELL - According to one embodiment, a modified piggyBac transposase polypeptide includes a piggyBac transposase amino acid sequence and a nuclear localization signal amino acid sequence. | 2022-06-23 |
20220195402 | ENPP1 POLYPEPTIDES AND METHODS OF USING SAME - The present disclosure includes ENPP1 mutant polypeptides with improved in vivo half-lives. | 2022-06-23 |
20220195403 | METHODS OF ACHIEVING HIGH SPECIFICITY OF GENOME EDITING - A method is disclosed for highly efficient DNA sequence alterations. The method is useful for editing chromosomes, to engineer cellular markers through insertion of genes, or to create epigenetic changes by using cas9-enzyme fusions where the enzymes can be DNA epigenetic modifying enzymes or chromatin modifying enzymes, etc. The technology also differs from all previously known technologies in that the CRISPR/Cas system can function in ways that are “clean”, i.e. they have not been in contact with any virus, or are carried DNA molecules that can insert into the chromosome in unintended locations. | 2022-06-23 |
20220195404 | LIPID-ENCAPSULATED DUAL-CLEAVING ENDONUCLEASE FOR DNA AND GENE EDITING - Methods to edit genes by administering a chimeric nuclease to a cell or organism without the use of a viral vector. | 2022-06-23 |
20220195405 | ENGINEERED SSDNASE-FREE CRISPR ENDONUCLEASES - The present disclosure provides compositions related to engineered CRISPR endonuclease proteins that have a reduced ability to non-specifically cleave single-stranded DNA (ssDNA) as compared to its reference wildtype protein. This disclosure also provides methods related to the use of, and generation of, engineered CRISPR endonuclease proteins that have a reduced ability to non-specifically cleave ssDNA as compared to its reference wildtype protein. | 2022-06-23 |
20220195406 | CRISPR/CAS-BASED GENOME EDITING COMPOSITION FOR RESTORING DYSTROPHIN FUNCTION - Disclosed herein are CRISPR/Cas-based genome editing compositions and methods for treating Duchenne Muscular Dystrophy by restoring dystrophin function. | 2022-06-23 |
20220195407 | OPTIMIZATION OF ENGINEERED MEGANUCLEASES FOR RECOGNITION SEQUENCES - The invention provides engineered meganucleases, derived from I-Crel, which have substitutions at particular positions that increase the activity of the nucleases for recognition sequences containing certain center sequences. The invention also provides methods of cleaving double-stranded DNA using such engineered meganucleases. The invention further provides methods for improving the activity of engineered meganucleases for recognition sequences containing certain center sequences. | 2022-06-23 |
20220195408 | COMBINATION CHEMOTHERAPY FOR THE TREATMENT OF CANCER - The present disclosure provides compositions, methods and kits for the treatment of cancer. Particularly, the present disclosure provides synergistic compositions comprising at least one cytotoxic ribonuclease and at least one MAPK-pathway inhibitor. | 2022-06-23 |
20220195409 | SIMULTANEOUS MULTIPLEX GENOME EDITING IN YEAST - The present disclosure provides compositions of matter, methods and instruments for editing nucleic acids in live yeast cells. | 2022-06-23 |
20220195410 | Xylanase Variants and Methods - The present invention relates to variant xylanase enzymes and their use thereof. | 2022-06-23 |
20220195411 | ENGINEERED BETA-GLUCOSIDASES AND GLUCOSYLATION METHODS - The present invention provides engineered β-glucosidase (BGL) enzymes, polypeptides having BGL activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. The present invention also provides compositions comprising the enzymes, and methods of using the engineered BGL enzymes to make products with β-glucose linkages. | 2022-06-23 |
20220195412 | METHOD OF PREPARING TOXIN - Disclosed are a medium composition for culturing | 2022-06-23 |
20220195413 | DRUG COCKTAIL ANALYSES USING MICROSCALE VORTEX-ASSISTED ELECTROPORATION - A vortex how based method for electroporating molecules, e.g., sequentially, into cells is provided. | 2022-06-23 |
20220195414 | Improved Manufacturing Procedures for Cell Based Therapies - CAR T cell therapies have shown promise in treating human blood cell cancer. The preparation of CAR T cells involves many complex, time consuming steps prior to infusion of the CAR T cells into a cancer patient. One step in the process to create CAR T cells often involves using magnetic separation technologies to isolate specific subsets of T cells prior to creating the CAR T cells. When using current magnetic separation technologies to remove undesired cell populations the recovery of the desired cell population can be as low as 50-70% or even lower and the procedures often take 30-60 minutes. In the case of autologous CAR T cell therapies such cell loss is often not acceptable. The present invention offers means to improve the recovery of desired cells to close to 100% very rapidly thus significantly improving a step in the manufacture of CART cells and in many cases will make such therapy possible for a larger patient population. | 2022-06-23 |
20220195415 | Nucleic Acid Constructs and Methods for Their Manufacture - The present invention concerns new artificially synthesized single stranded nucleic acid molecules which may be used in many applications, and templates and methods for making the same. There are a multitude of uses for single stranded nucleic acid molecules, including but not limited to vectors for the delivery of sequences (for example a gene sequence, or a template for gene editing, gene knock-in or knock-down) or in bioengineering, for example as for constructing highly ordered materials from nanoparticle building blocks. | 2022-06-23 |
20220195416 | RNA SITE-DIRECTED EDITING USING ARTIFICIALLY CONSTRUCTED RNA EDITING ENZYMES AND RELATED USES - Disclosed are RNA site-directed editing using artificially constructed RNA editing enzymes and related uses. Provided is the fusion of an RNA recognition domain for binding RNA and a functional effector domain to form a new functional protein. The new functional protein specifically targets target RNA by means of the recognition domain and performs RNA editing using the effector domain. | 2022-06-23 |
20220195417 | MULTIPLEX ASSEMBLY OF NUCLEIC ACID MOLECULES - Compositions and methods are provided herein for high throughput synthesis and assembly of nucleic acid molecules. Specific aspects include methods and rules for designing, grouping and pooling of nucleic acid molecules for efficient multiplex assembly, amplification, processing and analysis to obtain error-free assembly products. Provided compositions and methods allow for miniaturization, parallelization, high throughput production and scaling, and cost reduction in gene synthesis workflows. | 2022-06-23 |
20220195418 | CONTINUOUS DIRECTED EVOLUTION - The invention provides systems, methods, reagents, apparatuses, vectors, and host cells for the continuous evolution of nucleic acids. For example, a lagoon is provided in which a population of viral vectors comprising a gene of interest replicates in a stream of host cells, wherein the viral vectors lack a gene encoding a protein required for the generation of infectious viral particles, and wherein that gene is expressed in the host cells under the control of a conditional promoter, the activity of which depends on a function of the gene of interest to be evolved. Some aspects of this invention provide evolved products obtained from continuous evolution procedures described herein. Kits containing materials for continuous evolution are also provided. | 2022-06-23 |
20220195419 | METHODS FOR ISOLATING CELL-FREE DNA - Disclosed herein are methods for isolating DNA, such as cell-free DNA (cfDNA) or DNA from a tissue sample, e.g., in which the DNA is partitioned into hypermethylated and hypomethylated partitions. After differential tagging of the partitions, portions of the hypomethylated partition are pooled with the hypermethylated partition or pooled separately. Epigenetic and sequence-variable target regions are captured from the pool comprising DNA from the hypermethylated and hypomethylated partitions, and sequence-variable target regions are captured from the pool comprising DNA from the hypomethylated partition. This approach can reduce costs and/or bandwidth by limiting sequencing of epigenetic target regions from the hypomethylated partition, which may be less informative than other DNA. | 2022-06-23 |
20220195420 | METHODS AND SYSTEMS FOR DROPLET-BASED SINGLE CELL BARCODING - Methods and systems are provided for sample preparation techniques and sequencing of macromolecular constituents of cells and other biological materials. | 2022-06-23 |
20220195421 | BISTABLE POLYNUCLEOTIDE DEVICES FOR THE SENSING AND QUANTIFICATION OF MOLECULAR EVENTS - Bistable devices are constructed using a polynucleotide platform for the sensing of molecular events such as binding or conformational changes of target molecules. Uses include measurement of target concentration, measuring the effect of environmental condition (such as heat, light, or pH) on the target, or screening a library for molecules that bind the target or modulate its biological function. Devices comprise three regions: a top lid, bottom lid, and flexible linker or hinge between them. A device has an open configuration in which the top and bottom lid are separated, and a closed configuration they are bound close together. Binding domains or variations of the target molecule are fixed to a device so that when the molecular event occurs, the device switches from open to closed, or vice versa, which generates a signal. Devices carry DNA tags to enable separation of open and closed devices, as well as barcoding for multiplexed detection. | 2022-06-23 |
20220195422 | Nucleic Acid Library Methods - Provided herein are methods, compositions, and kits for removing a portion of a sequence in a member of a nucleic acid library. | 2022-06-23 |
20220195423 | CRISPR EDITING TO EMBED NUCLEIC ACID LANDING PADS INTO GENOMES OF LIVE CELLS - The present disclosure relates to compositions, methods, modules and automated integrated instrumentation for multiplex delivery of “landing pad” edits into the genomes of a population of live cells. The landing pads then may be leveraged to insert very large DNA sequences into the genomes of the population of live cells. | 2022-06-23 |
20220195424 | Chemical Capping for Template Switching - Provided herein is a method for chemically capping polynucleotides having a 5′ monophosphate. In some embodiments the method may comprise: combining an activated nucleoside 5′ mono- or poly-phosphate with a population of polynucleotides that comprises polynucleotides having a 5′ monophosphate, to produce a reaction mix; and incubating the reaction mix to produce reaction products that comprise a polynucleotide and a 5′ nucleoside cap, linked by a 5′ to 5′ polyphosphate linkage. The chemical capping method described herein can be incorporated into a variety of cDNA synthesis methods. | 2022-06-23 |
20220195425 | CHEMICALLY MODIFIED GUIDE RNAS FOR CRISPR/CAS-MEDIATED GENE REGULATION - Provided herein are methods for inducing CRISPR/Cas-based gene regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using modified single guide RNAs (sgRNAs) that enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a modified sgRNA to correct a mutation in a target gene associated with the genetic disease. | 2022-06-23 |
20220195426 | CHEMICALLY MODIFIED GUIDE RNAS FOR CRISPR/CAS-MEDIATED GENE CORRECTION - Provided herein are methods for inducing CRISPR/Cas-based gene regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using modified single guide RNAs (sgRNAs) that enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a modified sgRNA to correct a mutation in a target gene associated with the genetic disease. | 2022-06-23 |
20220195427 | COMPOSITIONS COMPRISING CHEMICALLY MODIFIED GUIDE RNAS FOR CRISPR/CAS-MEDIATED EDITING OF HBB - Provided herein are methods for inducing CRISPR/Cas-based gene regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using modified single guide RNAs (sgRNAs) that enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a modified sgRNA to correct a mutation in a target gene associated with the genetic disease. | 2022-06-23 |
20220195428 | OLIGONUCLEOTIDES AND METHODS FOR THE TREATMENT OF AGE-RELATED MACULARDEGENERATION - Disclosed are oligonucleotides, compositions, and methods that may be useful in the treatment of age-related macular degeneration (AMD). The treatment of age-regulated macular degeneration (AMD) may involve inhibiting an miR-33 target nucleic acid. For example, inhibition of an miR-33 target nucleic acid may be achieved using antisense oligonucleotides targeting an miR-33 target nucleic acid, interfering oligonucleotides targeting an miR-33 target nucleic acid, or recombinant AAV particles including a vector encoding an antisense oligonucleotide or interfering oligonucleotide targeting an miR-33 target nucleic acid. | 2022-06-23 |
20220195429 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF - Among other things, the present disclosure relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer. In some embodiments, a chirally controlled oligonucleotide composition has any sequence of bases, and/or pattern or base modifications, sugar modifications, backbone modifications and/or stereochemistry, or combination of these elements, described herein. | 2022-06-23 |
20220195430 | Compositions for Modulating Ataxin 2 Expression - Disclosed herein are antisense compounds and methods for decreasing Ataxin 2 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotropic sclerosis (ALS), and parkinsonism. | 2022-06-23 |
20220195431 | COMPOUNDS AND METHODS FOR REDUCING ATXN3 EXPRESSION - Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of ATXN3 RNA in a cell or animal, and in certain embodiments reducing the amount of ATXN3 protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such symptoms and hallmarks include motor dysfunction, aggregation formation, and neuron death. Such neurodegenerative diseases include spinocerebellar ataxia type 3(SCA3). | 2022-06-23 |
20220195432 | Methods for preventing and treating or diagnosing coronavirus infection - The present disclosure relates to a method for preventing and treating or diagnosing coronavirus infection. SARS-CoV2 lung infection animal models are established using rhesus macaques and human ACE2 transgenic mice, innate immune characteristics that occur in the body in the early stage of SARS-CoV2 infection are explored, and S100A8 protein is found as the root cause initiating the inflammatory storm and becomes an immune indicator for early diagnosis of a patient with SARS-CoV2 infection. Then inhibition of the function of S100A8/S100A9 dimer finally inhibits the virus titer in tissues, thereby decreasing the inflammation level, which proves that a dimer inhibitor can be used as an effective drug for preventing and treating coronavirus infection. | 2022-06-23 |
20220195433 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (SINA) - The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (MAO against target gene expression. | 2022-06-23 |
20220195434 | OVERSUBSCRIPTION SCHEDULING - A system for adjusting oversubscription loading includes an interface and a processor. The interface is configured to receive a set of performance data from a set of worker systems. The processor is configured to determine a feedback indication for a worker system of the set of worker systems based at least in part on the set of performance data. The feedback indication is used to adjust an oversubscription controller on the worker system. The processor is configured to provide the feedback indication to the worker system. | 2022-06-23 |
20220195435 | ANTISENSE OLIGONUCLEOTIDE AND DOUBLE STRANDED RNAS FOR CONTROL OF HEMIPTERAN AND LEPIDOPTERAN PESTS - The present disclosure provides oligonucleotides and double-stranded RNAs (dsRNAs) targeting Hemipteran and Lepidopteran insect pests. Bantam-sequence targets are detailed and shown to be effective targets for RNAi induction utilizing multiple dsRNAs, antisense oligonucleotides, and modified dsRNAs (e.g., 2′-O-methylated and dsRNAs containing non-canonical nucleosides). | 2022-06-23 |
20220195436 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF C3 IN A CELL - The invention relates to nucleic acid products that interfere with complement component C3 gene expression or inhibit its expression. The nucleic acids are preferably for use as treatment, prevention or reduction of risk of suffering from complement component C3 associated diseases, disorders or syndromes, particularly C3 Glomerulopathy (C3G), Paroxysmal Nocturnal Hemoglobinuria (PNH), atypical Hemolytic Uremic Syndrome (aHUS), Lupus nephritis, IgA nephropathy (IgA N), Cold Agglutinin Disease (CAD), Myasthenia gravis (MG), and Primary Membranous Nephropathy. | 2022-06-23 |
20220195437 | TAU-TARGETING OLIGONUCLEOTIDE GAPMERS - Antisense oligonucleotides are provided. These antisense oligonucleotides are useful in the preparation of gapmers for inhibition of Tau mRNA transcription. Inhibition of Tau mRNA transcription may result in decrease of amounts of Tau protein in a subject, allowing treatment of diseases and disorders related to expression of Tau, including Alzheimer's disease and primary tauopathies. | 2022-06-23 |
20220195438 | OLIGOMERS - Certain disclosed oligomers induce exon skipping during processing of myostatin pre-mRNA. The oligomers may be in a vector or encoded by the vector. The vector is used for inducing exon skipping during processing of myostatin pre-mRNA. A therapeutically effective amount of the oligomer may be administered to a subject patient such that exon skipping during processing of myostatin pre-mRNA is induced. The administration to a subject may be used in order to increase or maintain muscle mass, or slowing degeneration of muscle mass in the subject. The administration to a subject may ameliorate muscle wasting conditions, such as muscular dystrophy. Examples of such muscular dystrophies which may be so treated include Becker's muscular dystrophy, congenital muscular dystrophy, Duchenne muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy (FSHD), limb-girdle muscular dystrophy, myotonic muscular dystrophy, and oculopharyngeal muscular dystrophy. | 2022-06-23 |
20220195439 | TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Glial cell derived neurotrophic factor (GDNF), in particular, by targeting natural antisense polynucleotides of Glial cell derived neurotrophic factor (GDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of GDNF. | 2022-06-23 |
20220195440 | METHODS FOR TREATING CANCERS USING ANTISENSE - The present disclosure relates to compositions and methods for treating cancers using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In some embodiments, the AS are provides in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomem of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of cancer, for example glioblastoma. In some embodiments, the method are provided to predict the effectiveness of antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R) in a subject. | 2022-06-23 |
20220195441 | COMBINATORIAL CAR T CELL AND HEMATOPOEITIC STEM CELL GENETIC ENGINEERING FOR SPECIFIC IMMUNOTHERAPY OF MYELOID LEUKEMIAS - Some embodiments of the methods and compositions provided herein include chimeric antigen receptors (CAR)s which specifically bind to an epitope of CD33, such as an epitope encoded by exon 2 of CD33. Some embodiments include the use of such CARs for effective and safe therapies for myeloid leukemias, such as acute myeloid leukemia and chronic myeloid leukemia. | 2022-06-23 |
20220195442 | Protein Engineering via Error-Prone Orthogonal Replication and Yeast Surface Display - Disclosed herein are methods, compositions, and kits for engineering proteins using error-prone orthogonal replication (epOrthoRep) and yeast surface display (YSD). | 2022-06-23 |
20220195443 | CURING FOR RECURSIVE NUCLEIC ACID-GUIDED CELL EDITING - The present disclosure provides automated multi-module instrumentation and automated methods for performing recursive editing of live cells with curing of editing vectors from prior rounds of editing. | 2022-06-23 |
20220195444 | METHOD FOR THE TRANSIENT EXPRESSION OF NUCLEIC ACIDS IN PLANTS - Compositions and methods for transiently expressing proteins in a plant are provided. The compositions comprise plants, seeds, plant tissues, and plant parts expressing a protein, wherein the protein is expressed transiently and the transient expression of the protein can be used as a predictive model of how said protein will be expressed in stable transgenic plants in regards to qualitative and quantitative data. The predictive model may be used but is not limited to: promoter evaluation, evaluation of expression cassette construction for best performance (e.g. addition of enhancers or gene silencing suppressors), evaluation of best ways to express heterologous genes. | 2022-06-23 |
20220195445 | METHODS AND COMPOSITIONS FOR GENERATING DOMINANT SHORT STATURE ALLELES USING GENOME EDITING - The present disclosure provides compositions and methods for altering gibberellin (GA) content in corn or other cereal plants. Methods and compositions are also provided for altering the expression of genes related to gibberellin biosynthesis through editing of specific subtypes of GA20 oxidase genes to introduce an antisense sequence or segment into the gene. Modified plant cells and plants having a dominant allele reducing the expression or activity of one or more GA oxidase genes are further provided comprising reduced gibberellin levels and improved characteristics, such as reduced plant height and increased lodging resistance, but without off-types. | 2022-06-23 |
20220195446 | PLANT TRANSFORMATION - Plant cells and related systems, methods, and compositions for improving the capacity of the plant cells to regenerate embryogenic plant tissues, plant organs, and whole plants are provided. Such plant cells and related systems, methods, and compositions provide for increased expression of the endogenous morphoregulators BABYBOOM (ODP2) and/or WUSCHEL2 (WUS2). | 2022-06-23 |
20220195447 | PLANTS AND METHODS FOR PRODUCING 2-PYRONE-4, 6-DICARBOXYLIC ACID (PDC) - The present invention provides a genetically modified plant or plant cell comprising a nucleic acid encoding one or more heterologous enzymes operably linked a promoter, wherein one or more heterologous enzymes synthesizes 2-pyrone-4,6-dicarboxylic acid (PDC). | 2022-06-23 |
20220195448 | POLYPEPTIDE AND NUCLEIC ACID CAPABLE OF CHANGING AMYLOSE CONTENT (AC) IN PLANT, AND USE THEREOF - A mutant granule-bound starch synthase 1 (GBSS1) polypeptide and a nucleic acid, and use thereof are provided. Compared to an amino acid sequence of a parent GBSS1, the mutant GBSS1 polypeptide has a mutation at an amino acid corresponding to one or more of amino acid 237, amino acid 168, and amino acid 411 of an amino acid sequence shown in SEQ ID NO: 1. An amylose content (AC) in a plant changes after the plant undergoes GBSS1 mutation, which has very promising application prospects in the improvement of edible quality of rice. | 2022-06-23 |
20220195449 | METHODS TO INCREASE ANTIGENICITY OF MEMBRANE-BOUND POLYPEPTIDES PRODUCED IN PLANTS - Increased antigenicity of a membrane-bound polypeptide produced from a plant is provided in a process in which extraction of the polypeptide or other compounds from the plant is such that phospholipids are associated with the polypeptide. Reducing fat by supercritical fluid extraction increases antigenicity of such plant-produced membrane-bound polypeptides. Methods and means of producing such membrane-bound polypeptides are provided. Methods to produce a protective response in animals are provided by administering to the animal the membrane-bound polypeptide. Binding of antibody specific to the membrane-bound polypeptide is increased. The process provides for increased preferred formation of the membrane-bound polypeptide. Stability of the membrane-bound polypeptide is increased when the plant material is defatted. | 2022-06-23 |
20220195450 | METHODS AND COMPOSITIONS FOR GENERATING DOMINANT SHORT STATURE ALLELES USING GENOME EDITING - The present disclosure provides compositions and methods for altering gibberellin (GA) content in corn or other cereal plants. Methods and compositions are also provided for altering the expression of genes related to gibberellin biosynthesis through editing of a specific GA20 oxidase gene or locus to produce a genomic deletion or disruption that brings an antisense sequence of the GA20 oxidase gene under the control of a neighboring SAMT gene promoter. Modified plant cells and plants having a dominant allele reducing the expression or activity of one or more GA oxidase genes are further provided comprising reduced gibberellin levels and improved characteristics, such as reduced plant height and increased lodging resistance, but without off-types. | 2022-06-23 |
20220195451 | TRANSGENIC PLANTS HAVING INCREASED TOLERANCE TO ALUMINUM - Methods and materials for modulating aluminum tolerance in plants are disclosed. For example, nucleic acids encoding aluminum tolerance-modulating polypeptides are disclosed as well as methods for using such nucleic acids to transform plant cells. Also disclosed are plants having increased tolerance to aluminum and methods of increasing plant yield in soil containing elevated levels of aluminum. | 2022-06-23 |
20220195452 | TRANSGENIC PLANTS WITH ENHANCED TRAITS - This disclosure provides recombinant DNA constructs and transgenic plants having enhanced traits such as increased yield, increased nitrogen use efficiency, and enhanced drought tolerance or water use efficiency. Transgenic plants may include field crops as well as plant propagules and progeny of such transgenic plants. Methods of making and using such transgenic plants are also provided. This disclosure also provides methods of producing seed from such transgenic plants, growing such seed, and selecting progeny plants with enhanced traits. Also disclosed are transgenic plants with altered phenotypes which are useful for screening and selecting transgenic events for the desired enhanced trait. | 2022-06-23 |
20220195453 | METHOD FOR MODIFYING THE RESISTANCE PROFILE OF SPINACIA OLERACEA TO DOWNY MILDEW - The present invention relates to a method for modifying the resistance profile of a spinach plant to | 2022-06-23 |
20220195454 | BACTERIAL STRAINS WITH TOXIN COMPLEX FOR INSECT CONTROL - Biological strains, compositions, and methods of using the strains and compositions for reducing overall insect damage. | 2022-06-23 |
20220195455 | DELIVERY OF CRISPR/MCAS9 THROUGH EXTRACELLULAR VESICLES FOR GENOME EDITING - Disclosed herein is a fusion protein for gene editing, comprising a Cas9 domain that is configured to be encapsulated into exosomes and to localize to the nucleus of recipient cells. Also disclosed are recombinant polynucleotides that comprise a nucleic acid sequence encoding the disclosed Cas9 fusion protein. Also disclosed are cells comprising the disclosed polynucleotides. Also disclosed are methods of making a gene editing composition that involve culturing the disclosed cells under conditions suitable to produce extracellular vesicles encapsulating the guide RNA and fusion protein. Also disclosed are gene editing compositions that involve extracellular vesicles encapsulating the disclosed Cas9 fusion proteins and guide RNA. Finally, also disclosed herein are methods for editing a gene in a cell that involves contact the cell with the herein disclosed gene editing compositions. | 2022-06-23 |
20220195456 | CLOSED-ENDED LINEAR DUPLEX DNA FOR NON-VIRAL GENE TRANSFER - Aspects of the disclosure relate to a nucleic acid comprising a heterologous nucleic acid insert flanked by interrupted self-complementary sequences, wherein one self-complementary sequence is interrupted by a cross-arm sequence forming two opposing, lengthwise-symmetric stem-loops, and wherein the other of the self-complementary sequences is interrupted by a truncated cross-arm sequence. Methods of delivering the nucleic acid to a cell are also provided. | 2022-06-23 |
20220195457 | INTERNEURON-SPECIFIC THERAPEUTICS FOR NORMALIZING NEURONAL CELL EXCITABILITY AND TREATING DRAVET SYNDROME - Provided are therapeutic virus vectors, particularly, recombinant adeno-associated virus (rAAV) vectors, designed to contain an enhancer sequence that specifically restricts expression of an effector gene (e.g., an SCN1A-encoding polynucleotide, Gq-DREADD-encoding polynucleotide, or PSAM-encoding polynucleotide) contained in the vector to PV-expressing GABAergic interneuron or to neuron cell populations in the brain. The rAAV vectors, compositions and methods thereof are useful for treating subjects afflicted with neuropathologies, seizures, pharmacologically-intractable forms of epilepsy including Dravet syndrome (DS), a form of infantile epilepsy associated with severe seizures, cognitive impairment and premature death, as the cause of DS involves loss of function of a sodium channel encoded by the SCN1A gene. The described vectors restore expression of effector genes to the appropriate interneuron or neuron cell populations with specificity and sensitivity, advantageously to address the root cause of the disease by restoring the excitation-inhibition balance by means of gene-therapy (with SCN1A) or pharmacogenetics. | 2022-06-23 |
20220195458 | ENGINEERED ADENO-ASSOCIATED (AAV) VECTORS FOR TRANSGENE EXPRESSION - Engineered AAV vectors for transgene expression, e.g., in the CNS, PNS, inner ear, heart, or retina, and methods of use thereof. Also provided are methods for discovering new engineered AAV vectors that mediate transgene expression in desired cell types. | 2022-06-23 |
20220195459 | REGULATABLE EXPRESSION USING ADENO-ASSOCIATED VIRUS (AAV) - The present invention relates to viral particles which exhibit self-regulatory or regulatable features. | 2022-06-23 |
20220195460 | RETROVIRAL VECTOR HAVING IMMUNE-STIMULATING ACTIVITY - The disclosure provides vectors for treating cancers, method of producing such vectors and methods of use of the vectors. | 2022-06-23 |
20220195461 | METHODS AND COMPOSITIONS FOR TRANSGENE EXPRESSION - The disclosure provides methods of expressing a transgene in a cell, methods of treating disorders in a subject in need thereof, and pharmaceutical compositions. In particular, the methods involve contacting a cell (e.g., a cell of a subject suffering from a disorder such as cystic fibrosis) with a recombinant adeno-associated virus (rAAV) that includes, in one embodiment, an AV.TL65 capsid protein and a polynucleotide that includes a transgene in combination with an augmenter of AAV transduction, thereby expressing the transgene in the cell. The disclosure also provides pharmaceutical compositions that include an rAAV that includes, in one embodiment, an AV.TL65 capsid protein and a polynucleotide including a transgene in combination with one or more augmenters. | 2022-06-23 |
20220195462 | FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTIBODY THERAPEUTICS - Provided are methods and compositions for the delivery of fully human post-translationally modified therapeutic monoclonal antibodies and antigen-binding fragments thereof. The fully human post-translationally modified therapeutic monoclonal antibodies may be delivered by gene therapy methods, e.g., as a recombinant adeno-associated vims (rAAV) vector to the appropriate tissue. Methods of manufacture of the AAV vectors, pharmaceutical compositions and methods of treatment are also provided. In addition, provided are methods of producing therapeutic antibodies that are “biobetters” as fully human post-translationally modified. These fully human post-translationally modified therapeutic antibodies may be administered to a subject in need of treatment with the therapeutic antibody. | 2022-06-23 |
20220195463 | REPLICATIVE ONCOLYTIC ADENOVIRUS FOR REGULATING LIPID METABOLISM AND USE THEREOF - Provided are embodiments of replicative oncolytic adenovirus AD5 ApoA1 for inhibiting tumor growth and metastasis and use thereof in preparation of anti-tumor drugs. The virus can rapidly replicate in tumor cells and exert an oncolytic effect. Tumor cells infected with the virus can highly express apolipoprotein ApoA1 which can be secreted extracellularly in large quantities, significantly inhibit the invasion and metastasis of tumor cells, inhibit tumor-promoting inflammation pathways, and significantly reduce a IDO-1 which is a key molecule that leads to tumor immune escape. The virus can significantly inhibit tumor growth, inhibit tumor invasion, delay progression of cachexia and prolong the survival time of tumor-bearing mice in mice with liver cancer, breast cancer, colon cancer, or lung cancer. | 2022-06-23 |
20220195464 | NUCLEIC ACID-GUIDED NUCLEASES - Disclosed herein are nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Disclosed herein are engineered non-naturally occurring nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Targetable nuclease systems can be used to edit genetic targets, including recursive genetic engineering and trackable genetic engineering methods. | 2022-06-23 |
20220195465 | STABLE TARGETED INTEGRATION - Methods for integrating exogenous sequences in genomic loci, wherein the integration is stable and the exogenous sequence can function predictably and reliably. | 2022-06-23 |
20220195466 | PROCESS AND DEVICE FOR THE PRODUCTION OF METHANE - The present invention relates to a process for producing methane and to the device for producing methane, making it possible to increase the methane content of the outgoing gas and preferably simultaneously to increase the methane content of the outgoing gas and the productivity of the reactor. | 2022-06-23 |
20220195467 | DEHYDRATASE VARIANTS WITH IMPROVED SPECIFIC ACTIVITY FOR THE PRODUCTION OF PYRUVATE FROM GLYCERATE - Glycerol is a byproduct of biodiesel and bioethanol production and its conversion to value-added chemicals is a promising avenue for realization of the biorefinery concept Conversion of glycerol to pyruvate through glycerate yields pyruvate, is a common intermediate of many high-value natural products. The present invention aims at improving the specific activity of a naturally occurring enzyme toward conversion of glycerate to pyruvate (TvDHT). The present invention features compositions of isolated dehydratase enzyme (DHT) polypeptide composition, in particular the DHT polypeptide composition comprising a single point mutation that increases the specific activity of the enzyme as compared to wild type. | 2022-06-23 |
20220195468 | POLYHYDROXYALKANOATE PRODUCTION METHODS AND MATERIALS AND MICROORGANISMS USED IN SAME - Embodiments of the invention relate generally to methods to generate microorganisms and/or microorganism cultures that exhibit the ability to produce polyhydroxyalkanoates (PHA) from carbon sources at high efficiencies. In several embodiments, preferential expression of, or preferential growth of microorganisms utilizing certain metabolic pathways, enables the high efficiency PHA production from carbon-containing gases or materials. Several embodiments relate to the microorganism cultures, and/or microorganisms isolated therefrom. | 2022-06-23 |
20220195469 | CELL-FREE PRODUCTION OF GERANYL PYROPHOSPHATE FROM GLYCEROL IN A CELL-FREE MANUFACTURING SYSTEM - Geranyl pyrophosphate (GPP) is a key intermediate molecule in the bioproduction of thousands of natural products. Currently, natural products are either cultivated from plants, synthesized via complex chemical synthesis strategies, or through cell-based factories also known as biofoundries. However, in order to replicate the process in a cell free environment, numerous enzymes and cofactors must be utilized making this approach costly and unviable. In order to make this process viable, a new approach was needed that uses fewer enzymes and cofactors. As described herein, the present invention demonstrates that it is possible to create GPP from glycerol through a short and concise biosynthetic pathway outside of the cell. | 2022-06-23 |
20220195470 | L-TYROSINE-PRODUCING MICROORGANISM AND METHOD FOR PRODUCING L-TYROSINE USING THE SAME - The present disclosure relates to an L-tyrosine-producing microorganism, comprising a trp operon regulatory region and a gene encoding prephenate dehydratase operably linked thereto, and a method for producing L-tyrosine using the microorganism. | 2022-06-23 |
20220195471 | METHOD FOR RESOLVING OPTICAL ISOMER BY USING SUPERCRITICAL FLUID EXTRACTION TECHNOLOGY - Provided is a method for resolving an optical isomer from a racemate by using supercritical fluid extraction technology. The method is mainly applied to the separation of a product obtained after enzymatic resolution. Taking a preparation process of D-pantolactone as an example, the key point is to separate D-pantolactone and L-pantolactone from an enzymatic resolution liquid by means of supercritical fluid extraction. | 2022-06-23 |
20220195472 | BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS - Aspects of the disclosure relate to biosynthesis of cannabinoids and cannabinoid precursors in recombinant cells and in vitro. | 2022-06-23 |
20220195473 | GENES AND PROTEINS FOR AROMATIC POLYKETIDE SYNTHESIS - Nucleic acid molecules encoding polypeptides having polyketide synthase activity have been identified and characterized. Expression or over-expression of the nucleic acids alters levels of cannabinoid compounds in organisms. The polypeptides may be used in vivo or in vitro to produce cannabinoid compounds. | 2022-06-23 |
20220195474 | METABOLIC ENGINEERING OF NON-PATHOGENIC ESCHERICHIA COLI STRAINS FOR THE CONTROLLED PRODUCTION OF LOW MOLECULAR WEIGHT HEPAROSAN AND SIZE-SPECIFIC HEPAROSAN OLIGOSACCHARIDES - Methods for producing heparosan oligosaccharides and polysaccharides include culturing a recombinant host cell of a non-pathogenic | 2022-06-23 |
20220195475 | HYDROLYSIS OF BREWER'S SPENT GRAIN - A product hydrolysate from brewers' spent grain is disclosed, and the process for the preparation thereof, as well as uses thereof in food for humans and feed for animals. This hydrolysate contains a high percentage of pentosans at a low molecular weight which therefore offers a high bioavailability of soluble fibres. This allows the drawbacks associated with a high consumption of wholegrain products to be overcome, while also allowing consumers to benefit from the nutritional components contained therein. | 2022-06-23 |
20220195476 | METHOD AND KIT FOR REGENERATING REUSABLE INITIATORS FOR NUCLEIC ACID SYNTHESIS - A method for nucleic acid synthesis and regeneration of a reusable synthesis initiator includes incorporating a linking nucleotide to an immobilized initiator using a polymerase, synthesizing a nucleic acid right after the linking nucleotide using the polymerase, subjecting a substrate base of the linking nucleotide in the nucleic acid to base-excision by a DNA glycosylase to generate an abasic site, subjecting the abasic site to cleavage by an endonuclease to release the nucleic acid from the initiator, and converting the 3′ terminus of the initiator back to its original form by a 3′ phosphatase activity-possessing enzyme. A kit based on the aforesaid method and a method for regenerating a reusable initiator are also disclosed. | 2022-06-23 |